Imaging markers during PSMA therapy for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial is testing a new imaging approach during treatment with a radioactive drug (Lu-PSMA) for men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if imaging changes can help predict how well the treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with prostate cancer that has spread and is resistant to hormone therapy.
- Your cancer has gotten worse or you couldn't tolerate newer hormone drugs like abiraterone, enzalutamide, apalutamide, or darolutamide.
- You have already tried a type of chemotherapy called taxane, or your doctor has said you are too sick for chemotherapy.
- You are able to carry out daily activities with little or no help (ECOG score 0, 1, or 2).
- You agree to allow your medical data to be used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
This study is testing whether a special scan (dosimetry) can help predict how well PSMA radioligand therapy works for men with advanced prostate cancer that has spread. The therapy uses a radioactive drug to target and kill cancer cells that have a protein called PSMA.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
This early-phase study tests a new radioactive drug that targets PSMA, a protein on prostate cancer cells, to see if it can shrink tumors and slow the disease. It may be an option for men with advanced prostate cancer that has not responded to hormone therapy and possibly chemotherapy.
Hear when a new Prostate Cancer Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.